This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (November 2022) |
Mel Krajden OBC is a Canadian physician who is a professor of pathology and ;aboratory medicine at the University of British Columbia in Vancouver, British Columbia. He is the medical director of the BCCDC Public Health Laboratory.[1] Krajden obtained his BSc, MD, and FRCPC (Internal Medicine) at McGill University, followed by a fellowship in Infectious Diseases at Stanford University. He is also the medical director of the Public Health Laboratory at the British Columbia Centre for Disease Control. His research focuses on the prevention and care of hepatitis, human papillomavirus, and human immunodeficiency virus.
During the COVID-19 pandemic, Krajden played a key leadership role in Canada's public health response. Under his direction, the BC Centre for Disease Control, Public Health Laboratory, developed an accredited COVID-19 test within 10 days of the SARS-CoV-2 genome being released.[3] He was a leading member of the national government's COVID-19 Immunity Task Force. He led many COVID-19 research projects including:
- RESPOND in February 2020[4] to sequence the SARS-COV-2 genome from Genome British Columbia, part of Genome Canada,[5]
- R2ESPOND, a Canadian Institutes of Health Research funded project to research to link between genomic and heath outcomes for COVID-19 infections [6]
- EXPands, a project to address the world-wide reagent shortage at the beginning of the pandemic critical for patient testing to create reagents that could be validated in a College of American Pathologists accredited laboratory, and produced in scale meet the growing testing needs in British Columbia,[7]
- a project to link transmission metadata to viral genotype and serological responses of COVID-19,[8]
- SAfER a return-to-work study that tracked and collected data over time on infection, immunity, contacts, and clinical symptoms for 1,500 volunteer employees at BC based biotechnology companies,[9]
Krajden was also a collaborator on many COVID-19 research projects, including: COVID-19 Germline Analysis,[10] Immunological research on antibody and cell-mediated responses,[11] examining the biological properties of Variants of Concern and well therapeutics work,[12] the role ACEII plays,[13] and, the infection rate of COVID-19 in children and youths.[14]
Krajden serves on Health Canada's Expert Advisory Committee on Blood Regulation and Expert Advisory Committee on Cells, Tissues, and Organs. His role on these is because of his "expertise in medical microbiology, immunology, internal medicine and infectious diseases".[15] Krajden is also the Treasurer of the Association of Medical Microbiology and Infectious Disease Canada.[16]
In addition to more than 400 publications in peer-reviewed journals,[17] Krajden has been quoted in the lay press on subjects such as human metapneumovirus,[18] and SARS.[19]
Krajden was appointed as a member of the Order of British Columbia in 2020.[20]
References
edit- ^ "Mel Krajden".
- ^ "23rd Annual Life Sciences BC Awards presented by FARRIS".
- ^ "Meet DRDK Speaker Dr. Mel Krajden". 25 October 2020.
- ^ "BC to track origins and spread of new coronavirus with genomic technology". 20 February 2020.
- ^ "Response to Emerging Serious Pathogen Outbreaks using Next-gen Data (RESPOND) | COVID-19 Research".
- ^ https://covid19.research.ubc.ca/research/rapid-response-emerging-serious-pathogen-outbreaks-using-next-gen-data-r2espond, Archived 2021-09-24 at the Wayback Machine
- ^ "Securing Reagent Supplies and Scaling COVID-19 | COVID-19 Research".
- ^ "Linking Transmission Metadata to Viral Genotype and Serological Response of COVID-19 | COVID-19 Research".
- ^ "SARS-CoV-2 Study for Eased Restrictions in British Columbia – SAfER | COVID-19 Research".
- ^ "COVID-19 Germline Analysis: Germline analysis of patients infected with the COVID-19 coronavirus | COVID-19 Research".
- ^ "COVID-19 Immunological Investigation: Quality, quantity and kinetics of antibody and cell-mediated responses | COVID-19 Research".
- ^ "Profiling biological properties of SARS-CoV-2 VoCs and evaluating their susceptibility to therapeutics | COVID-19 Research".
- ^ "Prognostication of ACE II Receptor (PACEiiR) | COVID-19 Research".
- ^ "The SPRING Study: Severe acute respiratory syndrome-related coronavirus 2 prevalence in children and young adults in British Columbia: An observational study | COVID-19 Research".
- ^ "Expert Advisory Committee on Cells, Tisues, and Organs (EAC-CTO) - Membership List (updated June 2nd, 2011)". Health Canada. 2 June 2011. Retrieved 18 Mar 2015.
- ^ "2014-2015 AMMI Canada Council". Association of Medical Microbiology and Infectious Disease Canada. Archived from the original on 3 April 2015. Retrieved 18 March 2015.
- ^ "Mel Krajden".
- ^ "No proof virus was linked to seniors' deaths: B.C. officials". CBC News. 4 April 2008. Archived from the original on 8 June 2008. Retrieved 17 November 2010.
- ^ "B.C. Doctors work on experimental tests for SARS". CTV News. 21 April 2003. Archived from the original on 20 November 2007. Retrieved 17 November 2010.
- ^ "B.C.'s highest honour recognizes 13 British Columbians". Government of British Columbia. August 3, 2020.
 .svg){kind=small}  | This biography related to medicine in Canada is a stub. You can help Wikipedia by expanding it. |
 | This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it. |